De Witte J L, Kim J S, Sessler D I, Bastanmehr H, Bjorksten A R
Department of Anesthesia, University of California-San Francisco 94143-0648, USA.
Anesth Analg. 1998 Jul;87(1):173-9. doi: 10.1097/00000539-199807000-00036.
The analgesic tramadol inhibits the neuronal reuptake of norepinephrine and 5-hydroxytryptamine, facilitates 5-hydroxytryptamine release, and activates mu-opioid receptors. Each of these actions is likely to influence thermoregulatory control. We therefore tested the hypothesis that tramadol inhibits thermoregulatory control. Eight volunteers were evaluated on four study days, on which they received no drugs, tramadol 125 mg, tramadol 250 mg, and tramadol 250 mg with naloxone, respectively. Skin and core temperatures were gradually increased until sweating was observed and then decreased until vasoconstriction and shivering were detected. The core temperature triggering each response defined its threshold. Tramadol decreased the sweating threshold by -1.03 +/- 0.67 degrees C microgram-1.mL (r2 = 0.90 +/- 0.12). Tramadol also decreased the vasoconstriction threshold by -3.0 +/- 4.0 degrees C microgram-1.mL (r2 = 0.94 +/- 0.98) and the shivering threshold by -4.2 +/- 4.0 degrees C microgram-1.mL(r2 = 0.98 +/- 0.98). The sweating to vasoconstriction interthreshold range nearly doubled from 0.3 +/- 0.4 degree C to 0.7 +/- 0.6 degree C during the administration of large-dose tramadol (P = 0.04). The addition of naloxone only partially reversed the thermoregulatory effects of tramadol. The thermoregulatory effects of tramadol thus most resemble those of midazolam, another drug that slightly decreases the thresholds triggering all three major autonomic thermoregulatory defenses. In this respect, both drugs reduce the "setpoint" rather than produce a generalized impairment of thermoregulatory control. Nonetheless, tramadol nearly doubled the interthreshold range at a concentration near 200 ng/mL. This indicates that tramadol slightly decreases the precision of thermoregulatory control in addition to reducing the setpoint.
The authors evaluated the effects of the analgesic tramadol on the three major thermoregulatory responses: sweating, vasoconstriction, and shivering. Tramadol had only slight thermoregulatory effects. Its use is thus unlikely to provoke hypothermia or to facilitate fever.
镇痛药物曲马多可抑制去甲肾上腺素和5-羟色胺的神经元再摄取,促进5-羟色胺释放,并激活μ-阿片受体。这些作用中的每一种都可能影响体温调节控制。因此,我们检验了曲马多抑制体温调节控制的假说。8名志愿者在4个研究日接受评估,分别为不服药、服用125mg曲马多、服用250mg曲马多以及服用250mg曲马多加纳洛酮。皮肤温度和核心温度逐渐升高直至观察到出汗,然后降低直至检测到血管收缩和寒战。引发每种反应的核心温度定义了其阈值。曲马多使出汗阈值降低-1.03±0.67℃·μg⁻¹·mL(r² = 0.90±0.12)。曲马多还使血管收缩阈值降低-3.0±4.0℃·μg⁻¹·mL(r² = 0.94±0.98),使寒战阈值降低-4.2±4.0℃·μg⁻¹·mL(r² = 0.98±0.98)。在大剂量曲马多给药期间,出汗到血管收缩的阈间范围从0.3±0.4℃几乎翻倍至0.7±0.6℃(P = 0.04)。加用纳洛酮仅部分逆转了曲马多的体温调节作用。曲马多的体温调节作用因此最类似于咪达唑仑,另一种略微降低引发所有三种主要自主体温调节防御反应阈值的药物。在这方面,两种药物均降低“设定点”而非对体温调节控制产生全身性损害。尽管如此,曲马多在浓度接近200ng/mL时使阈间范围几乎翻倍。这表明曲马多除降低设定点外,还略微降低了体温调节控制的精度。
作者评估了镇痛药物曲马多对三种主要体温调节反应的影响:出汗、血管收缩和寒战。曲马多仅具有轻微的体温调节作用。因此其使用不太可能引发体温过低或促进发热。